Results of Operations and Financial Condition On August 13, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subjec…

Results of Operations and Financial Condition. On July 9, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 11.5% increase in product sales in Q2 of 2026 as compared to Q2 of 2025, based on preliminary, unaudited sales results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposed of Sec…

Regulation FD Disclosure In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equipment for expanded production of the Company’s flagship First Defense® product line. On June 4, 2026, ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program to execute on that strategy. The first phase, whic…

Results of Operations and Financial Condition On May 14, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject…

Entry into a Material Definitive Agreement On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies. As previously reported, that agreement expired March 31, 2026. Under the Settlement Deed, Norbrook has agreed to pay ImmuCell the s…

Director — Bryan K. Gathagan, Michael F. Brigham, Bobbi Jo Brockmann: Three long-serving directors are retiring from the Board.

Results of Operations and Financial Condition. On April 8, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 28.4% increase in product sales in Q1 of 2026 as compared to Q1 of 2025, based on preliminary, unaudited sales results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposed of S…

Director — Steven A. Rosgen: Mr. Rosgen is retiring from the Board, and Kathy V. Turner has been elected to fill the vacancy.

shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated March 4, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document ) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 4, 2026 IMMUCELL CORPORATION By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer Exh…

Director — Steven A. Rosgen, Bryan K. Gathagan: Two directors are not running for re-election due to time constraints from their full-time leadership roles.

Entry into a Material Definitive Agreement The information set forth in

Timothy C. Fiori, Bobbi Jo Brockmann: New employment agreements and compensatory arrangements for existing officers.

Results of Operations and Financial Condition On January 8, 2026, ImmuCell Corporation (the “Company”) issued a press release announcing its preliminary, unaudited sales results for the three-month and twelve-month periods ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto, and is incorporated herein by reference. The information in this report and the exhibit attached hereto are being furnished and shall not be deemed filed for purposes of the Securities…

Material Impairments. In its January 8, 2026 press release (see Exhibit 99.1, incorporated herein by reference), the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025. 1. As announced on December 24, 2025, the Company decided to pause further investment in Re-Tain® after receiving an FDA Incomplete Letter because the Company’s contract manufacturer had not satisfactorily addressed previousl…

ImmuCell Corporation (“ImmuCell”) has announced strategy changes (see

Results of Operations and Financial Condition On November 13, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise…

CEO — Michael F. Brigham: Michael F. Brigham stepped down as President, CEO, Secretary, and Treasurer and assumed the position of Special Advisor to the CEO.

shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated November 4, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: November 4, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exh…

shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated October 7, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: October 7, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive…

shall be deemed to be furnished, and not filed: 10.1 Employment Agreement between the Company and Olivier te Boekhorst dated as of September 29, 2025. 10.2 Confidential Information, Inventions and Noncompete Agreement between the Company and Olivier te Boekhorst, signed September 29, 2025 and effective upon commencement of employment. 99.1 Press Release of the Company dated September 29, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant…

Entry into a Material Definitive Agreement The information set forth in

President and Chief Executive Officer — Olivier te Boekhorst: The company has hired a new CEO from outside the organization.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information included in

Entry into a Material Definitive Agreement On August 20, 2025, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB) pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.

shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated August 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: August 14, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief E…